First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation

American Journal of Transplantation

Volumn 5, Issue 4 I, 2005, Pages 827-831

  Meiser, Bruno ^a   Reichert, Bruno ^a   Adamidis, Ioannis ^a   Überfuhr, Peter ^a   Kaczmarek, Ingo ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Calcineurin inhibitor free immunosuppression; Cardiac transplantation; Renal impairment

Indexed keywords

CALCINEURIN INHIBITOR; CHOLESTEROL; CORTICOSTEROID; CREATININE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; EDEMA; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DISEASE; MALE; PERICARDIAL EFFUSION; PILOT STUDY; PLEURA EFFUSION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CALCINEURIN; CREATININE; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE; LIPIDS; MALE; MIDDLE AGED;

EID: 16244393063     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00757.x     Document Type: Article

References (20)

1. Kobashigawa J, Miller L, Renlund D et al. for the mycophenolate Mofetil investigators. A randomized active-controlled trial of Mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507-515.
2. Meiser BM, Ueberfuhr P, Fuchs A et al. Single-center randomized trial comparing Tacrolimus (FK506) and Cyclopsorine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998; 17: 782-788.
3. Meiser BM, Pfeiffer M, Schmidt D et al. Combination therapy with Tacrolimus and Mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1998; 18: 143-149.
4. Eisen HJ, Tuzcu EM, Dorent R et al. for the RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-58.
5. Meiser BM, Groetzner J, Kaczmarek I et al. Tacrolimus or Cyclosporine-which is the better partner for Mycophenolate Mofetil in heart transplant recipients? Transplantation 2004; 78: 591-598.
6. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation. Transplantation 1997; 63: 664-668.
7. Aalamian Z. Reducing adverse effects of immunosuppressive agents in kidney transplant recipients. Prog Transplant 2001; 11: 271-282.
8. Behrend M. Adverse gastrointestinal effects of Mycophenolate Mofetil. Drug Safety 2001; 24: 645-663.
9. Oberbauer R, Kreis H, Johnson RW et al. for the Rapamune Maintenance Regimen Study Group. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364-370.
10. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000; 69: 2085-2090.
11. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
12. Groetzner J, Meiser B, Landwehr P et al. Mycophenolate Mofetil and Sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure Transplantation 2004; 77: 568-574.
13. Taylor DO, Barr ML, Radovancevic B et al. A randomized, multicenter comparison of Tacrolimus and Cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with Tacrolimus. J Heart Lung Transplant 1999; 18: 336-345.
14. Reichart B, Meiser B, Vigano M et al. European multicenter Tacrolimus (FK506) heart pilot study: one-year results - European Tacrolimus multicenter heart study group. J Heart Lung Transplant 1998; 17: 775-781.
15. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
16. Danovitch GM. Immunosuppressant-induced metabolic toxicities. Transplant Rev 2000; 14: 65-81.
17. Brattstrom C, Wilczek H, Tyden G, Bottiger Y, Sawe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65: 1272-1274.
18. Mueller M, Meiser B, Groetzner J, Kaczmarek I, Reichart B. Sirolimus in combination with Tacrolimus for primary immunosuppression after heart transplantation, J Heart Lung Transplant 2004; 23: S46.
19. Eisen HJ, Tuzcu EM, Dorent R et al. for the RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
20. Kobashigawa J, Tobis J, Mentzler RM et al. Further analysis of the intravascular ultrasound data from the randomized Mycophenolate Mofetil (MMF) trial in heart transplant recipients. J Heart Lung Transplant 2004; 23: S42.